Linked Life Data

18349364

Source:http://linkedlifedata.com/resource/pubmed/id/18349364

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
Pt 4
pubmed:dateCreated
2008-3-19
pubmed:abstractText
The increasing prevalence of community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA) poses a challenge for antimicrobial therapy of skin and soft tissue infections (SSTIs). To determine whether another antimicrobial agent might enhance the activity of moxifloxacin against CA-MRSA, this study analysed its activity alone and in chequerboard combination with doxycycline, rifampicin, clindamycin, trimethoprim, sulfamethoxazole/trimethoprim (SXT) and vancomycin against recent SSTI clinical isolates, and also characterized the isolates for Panton-Valentine leukocidin (PVL), agr groups, staphylococcal cassette chromosome mec (SSCmec) types and delta-haemolysin production. For comparison, 25 strains of outpatient meticillin-susceptible S. aureus (MSSA), 24 strains of healthcare-associated (HA)-MRSA and six historical strains of vancomycin-intermediate S. aureus (VISA) were included. It was found that 21/25 CA-MRSA strains tested were PVL-positive, SSCmec type 4 and agr type 1, whilst 4/25 were PVL-negative, SSCmec type 2 and agr type 2. Two of the agr type 2 strains were negative for delta-haemolysin but all other strains were positive. Moxifloxacin MIC50/90 values (microg ml(-1)) were 1/8 for CA-MRSA, 4/32 for HA-MRSA and <or=0.03/1 for MSSA and MIC50 of 2 for VISA. The D-test for inducible clindamycin resistance was positive for 3/27 CA-MRSA, 5/14 HA-MRSA and none of the MSSA isolates. In chequerboard studies, fractional inhibitory concentration indices (FICIs) showed that most interactions were additive or indifferent (FICI value >0.5 to <or=2) as follows: rifampicin 43/52 strains, clindamycin 44/44, SXT 44/47, trimethoprim 41/42 and vancomycin 37/43. The FICI values for doxycycline were 3-6 for 32/34 strains, indicating antagonism, suggesting that it should not be used in combination with moxifloxacin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-2615
pubmed:author
pubmed:issnType
Print
pubmed:volume
57
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
452-6
pubmed:meshHeading
pubmed-meshheading:18349364-Anti-Bacterial Agents, pubmed-meshheading:18349364-Aza Compounds, pubmed-meshheading:18349364-Bacterial Proteins, pubmed-meshheading:18349364-Community-Acquired Infections, pubmed-meshheading:18349364-Cross Infection, pubmed-meshheading:18349364-Drug Synergism, pubmed-meshheading:18349364-Drug Therapy, Combination, pubmed-meshheading:18349364-Humans, pubmed-meshheading:18349364-Methicillin, pubmed-meshheading:18349364-Methicillin Resistance, pubmed-meshheading:18349364-Microbial Sensitivity Tests, pubmed-meshheading:18349364-Quinolines, pubmed-meshheading:18349364-Soft Tissue Infections, pubmed-meshheading:18349364-Staphylococcal Infections, pubmed-meshheading:18349364-Staphylococcal Skin Infections, pubmed-meshheading:18349364-Staphylococcus aureus, pubmed-meshheading:18349364-Virulence, pubmed-meshheading:18349364-Virulence Factors
pubmed:year
2008
pubmed:articleTitle
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
pubmed:affiliation
R M Alden Research Laboratory, Santa Monica, CA 90404, USA. ejcgmd@aol.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't